

# Flavia Longo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2657621/publications.pdf>

Version: 2024-02-01

11  
papers

406  
citations

1307594

7  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

920  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of CT features and quantitative texture analysis in patients with thymic tumors: correlation with grading and staging. <i>Radiologia Medica</i> , 2018, 123, 345-350.	7.7	32
2	Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma. <i>Current Vascular Pharmacology</i> , 2018, 16, 190-196.	1.7	5
3	Evaluation of the efficacy of cisplatin+etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. <i>ERJ Open Research</i> , 2017, 3, 00128-2016.	2.6	20
4	Multimodality treatment of stage II thymic tumours. <i>Journal of Thoracic Disease</i> , 2017, 9, 2369-2374.	1.4	8
5	Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. <i>Scientific Reports</i> , 2016, 6, 31726.	3.3	232
6	Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. <i>Cancer Biology and Therapy</i> , 2016, 17, 79-82.	3.4	25
7	Development of a prediction model and risk score for procedure-related complications in patients undergoing percutaneous computed tomography-guided lung biopsy. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, e1-e6.	1.4	33
8	Merkel Cell Carcinoma of the Retroperitoneum with No Identifiable Primary Site. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-3.	0.3	2
9	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <i>OncoTargets and Therapy</i> , 2013, 6, 1761.	2.0	7
10	Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 105-109.	1.3	10
11	Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2011, 19, 1159-1164.	2.2	32